Zydus’ Doxycycline Hyclate Delayed-Release Tablets USP and Febuxostat Tablets Receives FDA’s Approval

•  Zydus’s doxycycline hyclate delayed-release tablets has received FDA approval for 75 mg, 100 mg and 150 mg to treat or prevent infections to susceptible bacteria
• Zydus has also received FDA approval for Febuxostat Tablets (US RLD – Uloric) 40 mg and 80 mg to treat hyperuricemia (constantly high levels of uric acid) in adults with gout and helps in reduction
  in pain, swelling, redness, heat, soreness, and stiffness in certain joints
• Additionally, Zydus has received 241 approvals with 340 ANDAs already filed

Click here to read full press release/ article | Ref: Zydus Cadila | Image:  etemaaddaily